Borgato S, Persani L, Romoli R, Cortelazzi D, Spada A, Beck-Peccoz P
Istituto di Scienze Endocrine, Università di Milano, Ospedale Maggiore IRCCS, Italy.
J Endocrinol Invest. 1998 Jun;21(6):372-9. doi: 10.1007/BF03350773.
It has been reported that serum FSH bioactivity and inhibin levels can be used as markers of the presence of true gonadotropin-secreting pituitary adenoma (Gn-oma). To verify this hypothesis, we have investigated the bioactivity of FSH and serum inhibin alpha-alpha and alpha-beta A levels in a series of patients with either Gn-oma or nonfunctioning pituitary adenoma (NFPA). Nine patients with Gn-oma (6 men and 3 women), 21 with NFPA (9 men and 12 women) and 30 normal subjects were included in the study. We studied FSH biological activity (FSH-B) by using Sertoli cell aromatase bioassay (SAB) and alpha-alpha and alpha-beta A inhibin levels by two noncompetitive immunometric assays (IEMA). In male patients with Gn-oma, serum immunoreactive FSH (FSH-I) and FSH-B levels ranged from 5.1 to 35.5 U/L and from 8.3 to 48 U/L, respectively, FSH B/I ratio being elevated in 2 (2.5 and 4.1; normal male range: 0.3-1.5), while female patients with Gn-oma had serum FSH-I and FSH-B levels ranging from 43.2 to 162 U/L and from 41.2 to 112.8 U/l, respectively, with a normal FSH B/I ratio. In male patients with NFPA, FSH-I and FSH-B levels ranged from 2.7 to 10.7 U/l and from 2.4 to 11.4 U/l while in females they ranged from 3.4 to 67.9 and from 4.6 to 60.8 U/l, respectively. FSH B/I ratio was elevated in 1 male (3.3) and normal in the remaining patients with NFPA. Serum alpha-alpha inhibin levels were normal or low in patients with Gn-oma and NFPA, while alpha-beta A inhibin concentrations were slightly elevated in 1 of 6 postmenopausal women (0.9; normal range < 0.7 U/ml). The present study confirms and extends previous reports indicating that male patients with Gn-oma may secrete FSH molecules with increased bioactivity. However, this abnormality was also observed in one male patient with NFPA. Moreover, the measurement of inhibin levels does not appear to be a reliable in vivo marker of pituitary tumors of gonadotroph origin, as it was normal or low in almost all patients with either Gn-oma or NFPA.
据报道,血清促卵泡生成素(FSH)生物活性和抑制素水平可作为真正分泌促性腺激素的垂体腺瘤(Gn瘤)存在的标志物。为验证这一假设,我们研究了一系列Gn瘤或无功能垂体腺瘤(NFPA)患者的FSH生物活性以及血清抑制素α-α和α-βA水平。该研究纳入了9例Gn瘤患者(6例男性和3例女性)、21例NFPA患者(9例男性和12例女性)以及30名正常受试者。我们通过使用支持细胞芳香化酶生物测定法(SAB)研究FSH生物活性(FSH-B),并通过两种非竞争性免疫测定法(IEMA)研究α-α和α-βA抑制素水平。在患有Gn瘤的男性患者中,血清免疫反应性FSH(FSH-I)和FSH-B水平分别为5.1至35.5 U/L和8.3至48 U/L,2例患者的FSH B/I比值升高(分别为2.5和4.1;正常男性范围:0.3 - 1.5),而患有Gn瘤的女性患者血清FSH-I和FSH-B水平分别为43.2至162 U/L和41.2至112.8 U/L,FSH B/I比值正常。在患有NFPA的男性患者中,FSH-I和FSH-B水平分别为2.7至10.7 U/L和2.4至11.4 U/L,而在女性患者中分别为3.4至67.9 U/L和4.6至60.8 U/L。1例患有NFPA的男性患者FSH B/I比值升高(3.3),其余患者正常。患有Gn瘤和NFPA的患者血清α-α抑制素水平正常或偏低,6例绝经后女性中有1例的α-βA抑制素浓度略有升高(0.9;正常范围<0.7 U/ml)。本研究证实并扩展了先前的报告,表明患有Gn瘤的男性患者可能分泌生物活性增加的FSH分子。然而,在1例患有NFPA的男性患者中也观察到了这种异常。此外,抑制素水平的测量似乎并不是促性腺激素来源垂体肿瘤可靠的体内标志物,因为在几乎所有患有Gn瘤或NFPA的患者中其水平正常或偏低。